DelveInsight’s, “Schizophrenia Pipeline Insight” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Schizophrenia pipeline landscape. It covers the Schizophrenia ...

AbbVie Inc . (NYSE:ABBV), currently trading at $190.14, has demonstrated resilience and strategic foresight as it navigates the loss of exclusivity for its blockbuster drug Humira. The ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.

After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...

Live Updates Deep Dive into ABBV's Earnings Call 11:53 am Looking through AbbVie’s earnings call, these growth prospects stood out: 1. Skyrizi & Rinvoq Set to Dominate Immunology Market 2025 revenue ...

Diluted EPS of $2.39 on a GAAP Basis, a Decrease of 12.1 Percent; Adjusted Diluted EPS of $10.12, a Decrease of 8.9 Percent; These Results Include ...

AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit margin of ...

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock ...

AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth ...

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

AbbVie also spoke about the disappointing data from Phase II studies of emraclidine in schizophrenia – a drug acquired as part of its $9bn acquisition of Cerevel. The company unveiled data in November ...